Patient Parameters and Other Radiation Safety Issues in 131i Therapy for Thyroid Cancer Treatment

Al-Haj, Abdalla N.; Lagarde, C; Lobriguito, Aida M.

doi:10.1097/01.hp.0000270274.66246.7e

Cited by 16 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Like other studies [4,9,21,28,40], the present study as well shows the mixed behaviour for stay of radioiodine administered patients concluding that more than 50% of hospitalized patients discharged within first 48 hours of administration of radioiodine. …”

Section: Resultssupporting

confidence: 80%

“…The hospitalization of patient in isolation room for a 1-3 days or more till fall of the radioactivity in their bodies or the exposure rate at one meter to acceptable levels play major role to avoid unsuitable high radiation exposure to patients' family members/ caregivers [9,22]. The radioiodine uptake and exposure rate differs from patient to patient so their stay at hospital may differ also.…”

Section: Discussionmentioning

confidence: 99%

“…Memon SA et al [4] studied that stay duration of only 1.2% patients was 24 hours and 33.73%, 25.3% & 21.67% were discharged from hospital after 48, 72 & 96 hours. Al Haj [9] revealed that only 7% of the total patients were stayed just for 24 hours where as 76% and 14% of patients stayed for 48 and 72 hours. Culver et al [21] reported that 26% of the treated patients were released after 24 hours from hospital whereas 67% and 7% were stayed for 48 and 72 hours respectively, Markou P et al [28] studied that 75% of patients stayed for 48 hours and only 25% discharged from hospital within 72 hours.…”

Section: Discussionmentioning

confidence: 99%

“…Data of patients (age, sex, activity administered, date and time of 131 I administration) were recorded [4,16]. Exposures rates at one meter from patients' bodies on the first day (at the time of activity administration), then consecutive days until the patients' hospital discharging day [3,9,17] were done with calibrated RM1001-RD LAMSE survey meter. Oral and written instructions about patients' isolation at hospital and at home were given for minimization of dose to others [4,5,9,16,[18][19][20].…”

Section: Methodsmentioning

confidence: 99%

“…To regulate the discharge of hospitalized 131 I administered patients, numerous standards and policies have been established [4]. The patients' releasing criteria is set to ensure that no family member/caregiver or general public receives exposures above the regulatory dose limits [3,5,[8][9][10][11]. This study was initiated to discuss the isolation period of inpatients treated with radioiodine.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Untitled

2017

IJRRT

View full text Add to dashboard Cite

Objectives: Since 1940s, the clinical use of unsealed radioisotopes has been in practice and after that the radioiodine's oral administration became a gold standard for treating thyroid cancers. To protect the patients' family members/ caregivers and general public from unacceptably high radiation exposures, the therapeutic dosage of 131 I administered patients are mandatory hospitalized in special isolation room until the exposure rate at one meter meets international and national limits. The current study was focused to measure the isolation duration of inpatients treated with radioiodine. Material and methods:The current study presents the duration of hospitalization of patients treated with 131 I therapeutic dosages at Nuclear Institute of Medicine & Radiotherapy (NIMRA) Jamshoro, Pakistan from 2011 to 2013. Thirty Five patients (age range from 18 to 70 years) with cancer of thyroid administered with different activities (50 to 200 mCi (milliCurie)) of 131 I admitted in special isolated room at different times were included in this study. Results:The results indicated that only one (2.86%) of total patients discharged from hospital within first 24 hours of 131 I administration whereas 17(48.57%), 11(31.43%) and 3(8.57%) patients were hospitalized in isolation room for 48, 72 and 96 hours after the administration of activity. Eleven percent of total isolated patients (n=4) stayed for 120 to 144 hours at the hospital. Conclusion:The stay duration of 131 I administered patients at NIMRA shows wide-ranging pattern. Due to rapid clearance of radioiodine form their bodies, more than half of patients stayed only 48 hours.

show abstract

Section: Resultssupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Untitled

2017

IJRRT

View full text Add to dashboard Cite

show abstract

Patient hospitalisation for radionuclide therapy should be the exception and not the norm

2022

View full text Add to dashboard Cite

Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia

Al-Mohammed

Sulieman

Mayhoub

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Worldwide, thyroid cancer accounts for some 10% of total cancer incidence, most markedly for females. Thyroid cancer radiotherapy, typically using 131I (T1/2 8.02 days; β− max energy 606 keV, branching ratio 89.9%), is widely adopted as an adjunct to surgery or to treat inoperable cancer and hyperthyroidism. With staff potentially receiving significant doses during source preparation and administration, radiation protection and safety assessment are required in ensuring practice complies with international guidelines. The present study, concerning a total of 206 patient radioiodine therapies carried out at King Faisal Specialist Hospital and Research Center over a 6-month period, seeks to evaluate patient and occupational exposures during hospitalization, measuring ambient doses and estimating radiation risk. Using calibrated survey meters, patient exposure dose-rate estimates were obtained at a distance of 30-, 100- and 300 cm from the neck region of each patient. Occupational and ambient doses were measured using calibrated thermoluminescent dosimeters. The mean and range of administered activity (AA, in MBq) for the thyroid cancer and hyperthyroidism treatment groups were 4244 ± 2021 (1669–8066), 1507.9 ± 324.1 (977.9–1836.9), respectively. The mean annual occupational doses were 1.2 mSv, that for ambient doses outside of the isolation room corridors were found to be 0.2 mSv, while ambient doses at the nursing station were below the lower limit of detection. Exposures to staff from patients being treated for thyroid cancer were less compared to hyperthyroidism patients. With a well-defined protocol, also complying with international safety requirements, occupational exposures were found to be relatively high, greater than most reported in previous studies.

show abstract

Patient Parameters and Other Radiation Safety Issues in 131i Therapy for Thyroid Cancer Treatment

Cited by 16 publications

References 18 publications

Untitled

Untitled

Patient hospitalisation for radionuclide therapy should be the exception and not the norm

Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia

Contact Info

Product

Resources

About